- Home
- BXMT vs KNSA Comparison
BXMT vs KNSA Comparison
Compare BXMT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXMT | KNSA |
|---|---|---|
| Founded | 1966 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BXMT | KNSA |
|---|---|---|
| Price | $18.18 | $59.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $21.38 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.2M | 522.3K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | 154.70 | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ N/A | $220.33 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $17.67 | $26.27 |
| 52 Week High | $20.67 | $59.94 |
Technical Indicators
Market Signals| Indicator | BXMT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 72.98 |
| Support Level | $17.98 | $40.67 |
| Resistance Level | $18.89 | $59.87 |
| Average True Range (ATR) | 0.32 | 1.93 |
| MACD | 0.03 | 1.00 |
| Stochastic Oscillator | 47.06 | 95.79 |
Price Performance
Historical ComparisonAbout BXMT Blackstone Mortgage Trust Inc.
Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.